848482-93-9

Basic information

• Product Name: (S)-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID
• Synonyms: (S)-PIPERAZINE-1,3-DICARBOXYLIC ACID 1-TERT-BUTYL ESTER;(S)-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID;(S)-4-(TERT-BUTOXYCARBONYL)PIPERAZINE-2-CARBOXYLIC ACID;4-BOC-PIPERAZINE-2-(S)-CARBOXYLIC ACID;(S)-1-Boc-piperazine-3-carboxylic acid;S-4-N-BOC-2-CARBOXYLIC ACID PIPERAZINE;S-4-N-BOC-2-PIPERIDINE CARBOXYLIC ACID;(S)-1-N-Boc-piperazine-3-carboxylic acid
• CAS NO: 848482-93-9
• Molecular Formula: C₁₀H₁₈N₂O₄
• Molecular Weight: 230.26
• Product Categories: pharmacetical;Piperaizine
• Mol File: 848482-93-9.mol
• Article Data: 6

Chemical Properties

• Melting Point: 231-239 ºC
• Boiling Point: 371.8 °C at 760 mmHg
• Flash Point: 178.6 °C
• Appearance: /
• Density: 1.193 g/cm³
• Storage Temp.: 2-8°C(protect from light)
• PKA: 2.20±0.20(Predicted)
• CAS DataBase Reference: (S)-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID(848482-93-9)
• EPA Substance Registry System: (S)-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID(848482-93-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36-43
• Safety Statements: 26-36/37
• Hazardous Substances Data: 848482-93-9(Hazardous Substances Data)

Usage

General Description

(S)-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID is a chemical compound that belongs to the class of piperazine carboxylic acids. It is a white, crystalline powder, and is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. The Boc (tert-butyloxycarbonyl) protecting group provides stability to the piperazine ring and allows for further functionalization. (S)-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID is often used as a building block in the production of various drugs and is important in the development of new therapeutic agents. Overall, (S)-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID plays a crucial role in the pharmaceutical and chemical industries.

Upstream product

• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 98-96-4 pyrazinamide 
• 1192014-44-0 C₈H₁₂N₂O₃ 
• 147650-70-2 (2S)-piperazine-2-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 73371-96-7 2-<<(tert-butoxycarbonyl)oxy>imino>-2-phenylacetonitrile 

Downstream Products

• 244132-27-2 (S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-4-(tert-butoxycarbonyl)piperazine-2-carboxylic acid 
• 1462904-46-6 C₁₄H₁₈N₂O₄*C₂HF₃O₂ 
• 314741-40-7 (3S)-3-(hydroxymethyl)-1-piperazinecarboxylic acid 1,1-dimethylethyl ester 
• 150323-37-8 N-(2(R)-hydroxy-1-(S)-indanyl)-2(R)-(phenylmethyl)-4(S)-<(tert-butyldimethylsilyl)oxy>-5-<1-<4-<(1,1-dimethylethoxy)carbonyl>-2(S)-(N-tert-butylcarbamoyl)piperazinyl>>pentanamide 
• 174139-99-2 2(R)-(phenylmethyl)-4(S)-<(tert-butyldimethylsilyl)oxy>-5-<1-<4-<(1,1-dimethylethoxy)carbonyl>-2(S)-(N-tert-butylcarbamoyl)piperazinyl>>pentanoic acid 
• 1027528-21-7 (S)-3-tert-Butylcarbamoyl-4-((2S,4R)-4-carboxy-2-hydroxy-5-phenyl-pentyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 150323-36-7 dihydro-5(S)-<<4-<(1,1-dimethylethoxy)carbonyl>-2(S)-(N-tert-butylcarbamoyl)piperazinyl>methyl>-3(R)-(phenylmethyl)-3(2H)-furanone 
• 150323-34-5 N-tert-butyl-4-<(1,1-dimethylethoxy)carbonyl>-1-<(phenylmethyl)carbonyl>piperazine-2(S)-carboxamide 
• 150378-17-9 indinavir 
• 150323-38-9 [14C]-N-Dealkyl Indinavir 
• 150323-35-6 t-butyl (S)-3-(tert-butylcarbamoyl)-piperazine-1-carboxylate 
• 150407-69-5 [2S]-1-benzyloxycarbonyl-4-t-butoxycarbonylpiperazine-2-carboxylic acid 
• 314741-38-3 1-benzyl 4-(tert-butyl) 2-methyl (2S)-piperazine-1,2,4-tricarboxylate 
• 1256387-23-1 (S,S,S,S)-(1-(2-(5-(4-(4-(2-(1-(2-methoxycarbonylamino-3-methylbutyryl)-4-(2,2,2-trifluoroethyl)piperazin-2-yl)-1H-imidazol-4-yl)phenylethynyl)phenyl)-1H-imidazol-2-yl)pyrrolidine-1-carbonyl)-2-methylpropyl)carbamic acid methyl ester 

Relevant articles and documents

RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USAGE THEREOF

The present invention discloses a receptor inhibitor of formula (I), a composition comprising the same and the usage thereof.

A traceless, solid-supported synthesis ofβ-turn mimetics based on the hexahydropyrazino[1,2-α ]pyrazine-1,2-dione scaffold

The solid-supported synthesis of a library of-turn mimetics based on the three-component Petasis condensation and 2,5-diketopiperazine formation is reported. The eight-step sequence starts from optically pure (S)-piperazine-2-carboxylic acid dihydrochloride, which is first converted into an orthogonally protected, resin-bound amino derivative. The subsequent transformations lead to compounds having the common hexahydropyrazino[1,2-a] pyrazine-1,2-dione core and diverse side chains, which mimic the-turn structure. This synthetic route includes protection of the initial amino acid with two different protecting groups, followed by attachment to the Wang resin using the Mitsunobu reaction, deprotection of the-nitrogen atom, then Petasis reaction, amidation, deprotection of the-nitrogen atom, coupling with a Boc-protected-amino acid, cleavage of the Boc group, and the cyclizative cleavage from the resin, resulting in the requested bicyclic products obtained in good yields and having good to moderate purities. Six different boronic acids, four amines, and nine-amino acids were applied to this synthetic route, to explore the efficiency and limitations of the described method. Georg Thieme Verlag Stuttgart.

COMPOUNDS AND METHODS FOR TREATMENT OF HCV

Aryl substituted pyrazole derivatives are provided, as well as processes for their preparation. The invention also provides compositions and methods for the treatment of HCV by administering a compound of the present invention, alone or in combination with additional antiviral agents, in a therapeutically effective amount.